---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004183"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:45:01.913159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reports preliminary FY2022 revenue ~$157.7M, extends cash runway to late 2025

## Summary
- Preliminary FY2022 total revenue ~$157.7M; XPOVIO US net revenue ~$120.4M, up 22% YoY.
- Q4 2022 total revenue ~$34.2M; XPOVIO US net revenue ~$31.1M.
- Cash & investments ~$279.0M as of Dec 31, 2022, following $165M private placement; runway extended to late 2025.
- Initiated Phase 3 EC-042 for selinexor in TP53 wild-type endometrial cancer; partnership with Foundation Medicine for companion Dx.
- Planning to initiate Phase 3 MF study in 1H 2023; updated Phase 1 selinexor+ruxolitinib data in MF expected in 1H 2023.

## SEC filing metadata
- accession: 0001193125-23-004183
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/0001193125-23-004183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/d435746d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004183
- JSON: https://secwatch.observer/filing/0001193125-23-004183.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004183.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported fourth quarter and full year 2022 results: revenue approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022.
  - Period: fourth quarter and full year 2022
  - Revenue: approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022
  - Result: preliminary results
  source text: On January 9, 2023, Karyopharm Therapeutics Inc. (the “Company”) announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates, and outlined its 2022 achievements and 2023 objectives.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/0001193125-23-004183-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.